AtriCure Inc. (NASDAQ:ATRC) COO Douglas J. Seith sold 36,363 shares of AtriCure stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $34.00, for a total value of $1,236,342.00. Following the completion of the sale, the chief operating officer now directly owns 131,743 shares in the company, valued at approximately $4,479,262. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of ATRC traded up $0.98 during mid-day trading on Thursday, reaching $36.28. The company’s stock had a trading volume of 5,772 shares, compared to its average volume of 204,504. AtriCure Inc. has a 1-year low of $22.57 and a 1-year high of $34.39. The stock has a market cap of $1.34 billion, a P/E ratio of -38.38 and a beta of 0.32. The business has a 50-day simple moving average of $31.57 and a two-hundred day simple moving average of $28.94. The company has a current ratio of 3.11, a quick ratio of 2.49 and a debt-to-equity ratio of 0.29.
AtriCure (NASDAQ:ATRC) last posted its earnings results on Wednesday, October 30th. The medical device company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $56.60 million for the quarter, compared to analyst estimates of $55.12 million. AtriCure had a negative return on equity of 13.59% and a negative net margin of 10.13%. The firm’s revenue was up 13.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.24) EPS. Research analysts anticipate that AtriCure Inc. will post -1.11 EPS for the current year.
A number of brokerages have commented on ATRC. Zacks Investment Research cut shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Tuesday, December 31st. BidaskClub upgraded shares of AtriCure from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 3rd. Finally, ValuEngine lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $36.00.
AtriCure Company Profile
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
Recommended Story: Pattern Day Trader
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.